China Chemical Regulatory China International Trade & Investment Government Affairs & Public Policy
ISLN:
909931467
Admitted:
Chinese National Bar
Law School:
Nanjing University in Nanjing, China, LL.B., 1993; Shanghai Academy of Social Science, LL.M., 1999; The George Washington University Law School, LL.M., 2002
Washington Eye Clinic 416 W Las Tunas Dr STE 304, San Gabriel, CA 91776 (626)5882518 (phone)
Education:
Medical School Louisiana State University School of Medicine at New Orleans Graduated: 1998
Procedures:
Lens and Cataract Procedures
Conditions:
Cataract Glaucoma Keratitis Retinal Detachments
Languages:
Chinese English
Description:
Dr. Huang graduated from the Louisiana State University School of Medicine at New Orleans in 1998. He works in San Gabriel, CA and specializes in Ophthalmology. Dr. Huang is affiliated with San Gabriel Valley Medical Center.
Ingrid Moulckers - Austin TX, US Robert A. Hood - Boca Raton FL, US Denise E. Frey - Rochester MN, US Ying Huang - Yorktown Heights NY, US Westley M. Clavey - Houston TX, US Stephen E. Bello - Austin TX, US
Assignee:
INTERNATIONAL BUSINESS MACHINES CORPORATION - Armonk NY
International Classification:
G06F 9/44
US Classification:
705 7
Abstract:
A method for creating and delivering customer solutions includes analyzing a customer's requirements; selecting at least one solution building block as part of a customer solution; and delivering at least one customer solution. The at least one solution building block comprises a preconfigured bundle of at least one asset comprising at least one of a hardware product, software product, service, or another solution building block. The at least one solution building block has been at least one of previously tested or successfully deployed in a customer environment for solving a business, infrastructure, or application problem.
Youtube
Ying Huang Ken Noda - Puccini La Boheme - Qua...
Ying Huang (Soprano, Metropolitan Opera) and Ken Noda (Piano, Metropol...
Duration:
2m 59s
Stille Nacht / Silent Night - Placido Domingo...
Merry Christmas from Vienna.
Duration:
7m 56s
Puccini - Mme Batterfly - Un bel di, vedremo ...
Rosa, here's your video Ying Huang is a Chinese operatic soprano. She ...
Duration:
4m 29s
Ying Huang: "Con onor muore" (Madame Butterfly)
Ying Huang performs the powerful finale of Giacomo Puccini's opera "Ma...
Duration:
4m 32s
Christmas in Vienna IV (1997)
Spanish operatic tenor Plcido Domingo, Chinese operatic soprano Ying H...
Duration:
1h 30m 58s
Live in a world with multiple memory types - ...
Live in a world with multiple memory types - Ying Huang --- The Linux ...
Duration:
42m 58s
News
Chinese COVID-19 Vaccine Phase 2 Trial Results: Safe and Induces an Immune Response
Reference: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial by Feng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, Jian-Ying Huang, Tao Jiang, Li-Hua Hou, Jing-Xin Li, Be
Date: Jul 20, 2020
Category: More news
Source: Google
Gilead Sciences, Inc Stock May Be in For a Rally Ahead of EASL
According to Merrill Lynch analyst Ying Huang who has also commented on the published abstracts Gileads 24-week sof/vel combo drug with or without ribavirin delivered a retreatment option for patients who failed initial treatment with the same combo med for 8-12 weeks. An 8-week triple combinat
Date: Apr 01, 2016
Category: Business
Source: Google
Cost of Gilead's hepatitis C pill, Sovaldi, spurs revolt
"It's just the sheer number of patients who have the disease. Multiply that number by that price," said Ying Huang, a senior biotechnology analyst at Barclays, whose clients include Gilead. "All of a sudden, you get a big number."
approved in 100 countries for kidney cancer and liver cancer, are split between Bayer and Onyx. The drug had sales of roughly $900 million last year. An expanded approval for thyroid cancer could result in an additional $300 million in peak global sales annually, said Ying Huang, a Barclays analyst.
Date: Jun 02, 2013
Category: Health
Source: Google
GlaxoSmithKline extends tender offer for Human Genome Sciences
"We continue to believe the most likely outcome will be a slightly higher bid from GSK, with no white knights coming to the table with a substantially higher bid," said Ying Huang and Brian Bourdot at Barclays Capital.